These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

306 related articles for article (PubMed ID: 28699428)

  • 1. Thyrotropin Suppressive Therapy for Low-Risk Small Thyroid Cancer: A Propensity Score-Matched Cohort Study.
    Park S; Kim WG; Han M; Jeon MJ; Kwon H; Kim M; Sung TY; Kim TY; Kim WB; Hong SJ; Shong YK
    Thyroid; 2017 Sep; 27(9):1164-1170. PubMed ID: 28699428
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Management of papillary and follicular (differentiated) thyroid cancer: new paradigms using recombinant human thyrotropin.
    Mazzaferri EL; Massoll N
    Endocr Relat Cancer; 2002 Dec; 9(4):227-47. PubMed ID: 12542401
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Dynamic Risk Stratification for Predicting Recurrence in Patients with Differentiated Thyroid Cancer Treated Without Radioactive Iodine Remnant Ablation Therapy.
    Park S; Kim WG; Song E; Oh HS; Kim M; Kwon H; Jeon MJ; Kim TY; Shong YK; Kim WB
    Thyroid; 2017 Apr; 27(4):524-530. PubMed ID: 27869547
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Clinical experience with recombinant human thyrotrophin (rhTSH) in the management of patients with differentiated thyroid cancer.
    Mariani G; Ferdeghini M; Augeri C; Villa G; Taddei GZ; Scopinaro G; Boni G; Bodei L; Rabitti C; Molinari E; Bianchi R
    Cancer Biother Radiopharm; 2000 Apr; 15(2):211-7. PubMed ID: 10803328
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Patients with differentiated thyroid cancer who underwent radioiodine thyroid remnant ablation with low-activity ¹³¹I after either recombinant human TSH or thyroid hormone therapy withdrawal showed the same outcome after a 10-year follow-up.
    Molinaro E; Giani C; Agate L; Biagini A; Pieruzzi L; Bianchi F; Brozzi F; Ceccarelli C; Viola D; Piaggi P; Vitti P; Pacini F; Elisei R
    J Clin Endocrinol Metab; 2013 Jul; 98(7):2693-700. PubMed ID: 23626005
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Thyrotropin suppression and disease progression in patients with differentiated thyroid cancer: results from the National Thyroid Cancer Treatment Cooperative Registry.
    Cooper DS; Specker B; Ho M; Sperling M; Ladenson PW; Ross DS; Ain KB; Bigos ST; Brierley JD; Haugen BR; Klein I; Robbins J; Sherman SI; Taylor T; Maxon HR
    Thyroid; 1998 Sep; 8(9):737-44. PubMed ID: 9777742
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Non-suppressed thyrotropin and elevated thyroglobulin are independent predictors of recurrence in differentiated thyroid carcinoma.
    Böhm J; Kosma VM; Eskelinen M; Hollmen S; Niskanen M; Tulla H; Alhava E; Niskanen L
    Eur J Endocrinol; 1999 Nov; 141(5):460-7. PubMed ID: 10576761
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Postoperative Thyroid-Stimulating Hormone Levels Did Not Affect Recurrence after Thyroid Lobectomy in Patients with Papillary Thyroid Cancer.
    Lee MC; Kim MJ; Choi HS; Cho SW; Lee GH; Park YJ; Park DJ
    Endocrinol Metab (Seoul); 2019 Jun; 34(2):150-157. PubMed ID: 31099202
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Stimulated thyroglobulin values above 5.6 ng/ml before radioactive iodine ablation treatment following levothyroxine withdrawal is associated with a 2.38-fold risk of relapse in Tg-ab negative subjects with differentiated thyroid cancer.
    Mousa U; Yikilmaz AS; Nar A
    Clin Transl Oncol; 2017 Aug; 19(8):1028-1034. PubMed ID: 28258491
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Low trabecular bone score in postmenopausal women with differentiated thyroid carcinoma after long-term TSH suppressive therapy.
    De Mingo Dominguez ML; Guadalix Iglesias S; Martin-Arriscado Arroba C; López Alvarez B; Martínez Diaz-Guerra G; Martinez-Pueyo JI; Ferrero Herrero E; Hawkins Carranza F
    Endocrine; 2018 Oct; 62(1):166-173. PubMed ID: 30014437
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Prediction of thyroid hormone supplementation after thyroid lobectomy.
    Lee DY; Seok J; Jeong WJ; Ahn SH
    J Surg Res; 2015 Jan; 193(1):273-8. PubMed ID: 25088372
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effects of short-term metformin therapy associated with levothyroxine dose decrement on TSH and thyroid hormone levels in patients with thyroid cancer.
    Mousavi Z; Dourandish L; Rokni H; Sadeghi R; Rasoul Zakavi S
    Minerva Endocrinol; 2014 Mar; 39(1):59-65. PubMed ID: 24513605
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effects of endocrine therapy on the prognosis of elderly patients after surgery for papillary thyroid carcinoma.
    Xia Q; Dong S; Bian PD; Wang J; Li CJ
    Eur Arch Otorhinolaryngol; 2016 Apr; 273(4):1037-43. PubMed ID: 25744048
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Thyrotropin suppression increases the risk of osteoporosis without decreasing recurrence in ATA low- and intermediate-risk patients with differentiated thyroid carcinoma.
    Wang LY; Smith AW; Palmer FL; Tuttle RM; Mahrous A; Nixon IJ; Patel SG; Ganly I; Fagin JA; Boucai L
    Thyroid; 2015 Mar; 25(3):300-7. PubMed ID: 25386760
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Ablation of thyroid residues with 30 mCi (131)I: a comparison in thyroid cancer patients prepared with recombinant human TSH or thyroid hormone withdrawal.
    Pacini F; Molinaro E; Castagna MG; Lippi F; Ceccarelli C; Agate L; Elisei R; Pinchera A
    J Clin Endocrinol Metab; 2002 Sep; 87(9):4063-8. PubMed ID: 12213846
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Recombinant human TSH use in differentiated thyroid cancer].
    Graf H; Paz-Filho G
    Arq Bras Endocrinol Metabol; 2007 Jul; 51(5):806-12. PubMed ID: 17891244
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Patient Age Is an Independent Risk Factor of Relapse of Differentiated Thyroid Carcinoma and Improves the Performance of the American Thyroid Association Stratification System.
    Trimboli P; Piccardo A; Signore A; Valabrega S; Barnabei A; Santolamazza G; Di Paolo A; Stati V; Chiefari A; Vottari S; Simmaco M; Ferrarazzo G; Ceriani L; Appetecchia M; Giovanella L
    Thyroid; 2020 May; 30(5):713-719. PubMed ID: 31973653
    [No Abstract]   [Full Text] [Related]  

  • 18. Use of recombinant human thyrotropin before radioiodine therapy in patients with advanced differentiated thyroid carcinoma.
    Luster M; Lassmann M; Haenscheid H; Michalowski U; Incerti C; Reiners C
    J Clin Endocrinol Metab; 2000 Oct; 85(10):3640-5. PubMed ID: 11061516
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Follow-up of low-risk differentiated thyroid cancer patients who underwent radioiodine ablation of postsurgical thyroid remnants after either recombinant human thyrotropin or thyroid hormone withdrawal.
    Elisei R; Schlumberger M; Driedger A; Reiners C; Kloos RT; Sherman SI; Haugen B; Corone C; Molinaro E; Grasso L; Leboulleux S; Rachinsky I; Luster M; Lassmann M; Busaidy NL; Wahl RL; Pacini F; Cho SY; Magner J; Pinchera A; Ladenson PW
    J Clin Endocrinol Metab; 2009 Nov; 94(11):4171-9. PubMed ID: 19850694
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Blood thyroglobulin and TSH receptor mRNA detection by RT-PCR in the follow-up of differentiated thyroid cancer patients.
    Torosian L; Manrique G; Alvarez B; Lago G; Roca R; Belzarena C
    Rev Esp Med Nucl; 2010; 29(3):109-13. PubMed ID: 20399540
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.